Galena Biopharma, Inc. (NASDAQ:GALE) belonging to the Medical sector which declined -4.74% and closed its last trading session at $0.33.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/14/2016. Currently, the stock has a 1 Year Price Target of $1.13.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Galena Biopharma, Inc. on 6/30/2016 reported its EPS as $0.03 with the analysts projecting the EPS of the stock as $-0.06. The company beat the analyst EPS Estimate with the difference of $0.09. This shows a surprise factor of 150%.
Many analysts have provided their estimated foresights on Galena Biopharma, Inc. Earnings, with 3 analysts believing the company would generate an Average Estimate of $-0.04. Whereas they predicted High and Low Earnings Estimate as $-0.03 and $-0.06 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.11.
The Company got Downgrade by Raymond James on 29-Jun-16 from Outperform to Mkt Perform.
Insider Trades for Galena Biopharma, Inc. show that the latest trade was made on 30 Jun 2016 where Schwartz Mark W, the Chief Executive Officer completed a transaction type “Buy” in which 8503 shares were traded at a price of $0.4.
3 analysts projected Price Targets for Galena Biopharma, Inc. The analysts believe that the company stock price could grow as high as $2. The Low Price target projection by analysts is $0.4 and the Mean Price Target is $1.13.
Galena Biopharma, Inc. (NASDAQ:GALE) has the market capitalization of $67.16 Million. The company rocked its 52-Week High of $2.49 on Jun 20, 2016 and touched its 52-Week Low of $0.28 on Jun 29, 2016. The stock has Return on Assets (ROA) of -64 percent. Return on Equity (ROE) stands at -248.2% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -77.32 Percent. The company has Beta Value of 2.12 and ATR value of 0.03. The Weekly and Monthly Volatility stands at 7.37% and 7.99%.
Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon.